Related Experiment Video
Updated: Mar 19, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT
Yang Wang1,2, Ning Shao1,2, Xueying Mao3
1Department of Urology, Affiliated Wuxi No. 2 Hospital of Nanjing Medical University, Wuxi, China.
Abstract:
MicroRNAs (miRNAs) are short, conserved segments of non-coding RNA which play a significant role in prostate cancer development and progression. To identify miRNAs associated with castration resistance, we performed miRNA microarray analysis comparing castration resistant prostate cancer (CRPC) with androgen dependent prostate cancer (ADPC). We identified common underexpression of miR-4638-5p in CRPC compared to ADPC samples, which were further confirmed by quantitative PCR analysis. The role of miR-4638-5p in prostate cancer androgen-independent growth has been demonstrated both in vitro and in vivo. We also identified Kidins220 as a target gene directly regulated by miR-4638-5p and shRNA-mediated knockdown of Kidins220 phenocopied miR-4638-5p restoration. Subsequently, we revealed that Kidins220 activates PI3K/AKT pathway, which plays a key role in CRPC. Loss of miR- 4638-5p may lead to CRPC through the activity of Kidins220 and PI3K/AKT pathway. Furthermore, we found that miR-4638-5p, through regulating Kidins220 and the downstream activity of VEGF and PI3K/AKT pathway, influences prostate cancer progression via angiogenesis. The identification of miR-4638-5p down-regulation in CRPC and the understanding of the functional role of miR-4638-5p and its downstream genes/pathways have the potential to develop biomarkers for CRPC onset and to identify novel targets for novel forms of treatments of this lethal form of PCa.
Insights
MicroRNA miR-4638-5p is underexpressed in castration-resistant prostate cancer (CRPC). Its loss promotes CRPC growth via Kidins220 and the PI3K/AKT pathway, offering potential therapeutic targets.
Area of Science:
- Molecular Oncology
- Cancer Biology
- Biochemistry
Background:
- MicroRNAs (miRNAs) are crucial regulators in prostate cancer progression.
- Castration-resistant prostate cancer (CRPC) remains a significant clinical challenge.
- Identifying molecular drivers of CRPC is essential for developing new therapies.
Purpose of the Study:
- To identify microRNAs associated with the development of castration resistance in prostate cancer.
- To elucidate the functional role of miR-4638-5p in prostate cancer progression.
- To investigate the downstream targets and pathways regulated by miR-4638-5p.
Main Methods:
- MicroRNA microarray analysis comparing CRPC and androgen-dependent prostate cancer (ADPC) samples.
- Quantitative PCR (qPCR) for miRNA expression validation.
- In vitro and in vivo functional assays to assess miR-4638-5p's role.
- Target gene identification and pathway analysis (e.g., Kidins220, PI3K/AKT, VEGF).
Main Results:
- miR-4638-5p was commonly underexpressed in CRPC compared to ADPC.
- Restoration of miR-4638-5p inhibited androgen-independent growth of prostate cancer cells.
- Kidins220 was identified as a direct target of miR-4638-5p, and its knockdown mimicked miR-4638-5p restoration.
- Kidins220 activates the PI3K/AKT pathway, crucial for CRPC.
- miR-4638-5p regulates angiogenesis via Kidins220, VEGF, and the PI3K/AKT pathway.
Conclusions:
- Downregulation of miR-4638-5p contributes to CRPC development and progression.
- The miR-4638-5p/Kidins220/PI3K/AKT axis is a key pathway in CRPC.
- miR-4638-5p influences angiogenesis, impacting prostate cancer progression.
- miR-4638-5p and its downstream effectors represent potential biomarkers and therapeutic targets for CRPC.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
MicroRNAs
MicroRNAs

